Skip to content

Clinical trials

Observational Retinal Degeneration trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Retinal Degeneration Phase: Observational Clear all

31 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20061
20111
20121
20132
20151
20163
20172
20181
20193
20201
20212
20237
20241
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed10
Active, not recruiting7
Recruiting5
Unknown status3
Not yet recruiting2
Enrolling by invitation2
Terminated2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Nanoscope Therapeutics Inc.4
National Eye Institute (NEI)4
4D Molecular Therapeutics1
Adverum Biotechnologies, Inc.1
Beacon Therapeutics1
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts1
Complement Therapeutics1
Editas Medicine, Inc.1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS1
Food and Drug Administration (FDA)1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Retinal Degeneration31
Retinitis Pigmentosa14
Retinal Diseases9
Eye Diseases8
Macular Degeneration8
Retinal Dystrophies7
Eye Diseases, Hereditary5
Stargardt Disease4
Choroideremia3
Diabetic Retinopathy3

Trials

Showing 76 to 31 of 31. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.